WXIBF
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 0.63 | $11.6B | $2.8B |
| 2025 Q2 | 0.58 | $10.0B | -$94M |
| 2024 Q4 | 0.46 | $10.1B | $1.9B |
| 2024 Q2 | 0.35 | $8.6B | -$565M |
| 2023 Q4 | 0.26 | $8.5B | $219M |
| 2023 Q2 | 0.52 | $8.5B | $219M |
| 2022 Q4 | 0.42 | $8.1B | $900M |
| 2022 Q2 | 0.58 | $7.2B | -$1.2B |